Alefacept: A review of the literature and practical guidelines for management

Dermatologic Therapy

Volumn 17, Issue 5, 2004, Pages 383-392

  Hodak, Emmilia ^a,b   David, Michael ^a,b  

^a RABIN MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Biologics; CD2; Memory T cells; Psoriasis; Therapy

Indexed keywords

ALEFACEPT;

ARTHRALGIA; ASTHENIA; CHILL; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; HEADACHE; HUMAN; INFECTION; LYMPHOCYTE; NAUSEA; PAIN; PHARYNGITIS; PRACTICE GUIDELINE; PRURITUS; PSORIASIS; REVIEW; RHINITIS; VIRUS INFECTION;

CLINICAL TRIALS, PHASE III; HUMANS; PRACTICE GUIDELINES; PSORIASIS; RECOMBINANT FUSION PROTEINS; SEVERITY OF ILLNESS INDEX;

EID: 6344287937     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1396-0296.2004.04041.x     Document Type: Review

References (43)

1. Krueger JG. Pathogenic interactions of keratinocytes and T lymphocytes in psoriasis. In: Roenigk HH, Maibach HI, eds. Psoriasis. New York: Marcel Dekker, 1998: 315-327.
2. +) in both normal and diseased human skin. Arch Dermatol Res 1989: 281: 24-30.
3. Friedrich M, Kramming S, Henze M, Docke WD, Sterry W, Asadullah K. Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type one immunophenotype. Arch Dermatol Res 2000: 292: 519-521.
4. Jeffes EW III, Lee GC, Said S, et al. Elevated numbers of proliferating mononuclear cells in the peripheral blood of psoriatic patients correlate with disease severity. J Invest Dermatol 1995: 105: 733-738.
5. + T cells in the blood of psoriasis patients correlates closely with the severity of their disease. Clin Exp Immunol 2001: 126: 365-369.
6. Ellis CN, Gorsulowsky DC, Hamilton T, et al. Cyclosporine improves psoriasis in a double-blind study. JAMA 1986: 256: 3110-3116.
7. Callen JP, Krueger GG, Lebwohl M, et al. AAD consensus statement on psoriasis therapies. J Am Acad Dermatol 2003: 49: 897-899.
8. Ozawa M, Ferenczi K, Kikuchi T, et al. 312-nanometer ultraviolet B light (narrow-band UVB) induces apoptosis of T cells within psoriatic lesions. J Exp Med 1999: 189: 711-718.
9. Johnson R, Stainano-Coico L, Austin L, Cardinale I, Nabeya-Tsukifuji R, Krueger G. PUVA treatment selectively induces a cell cycle block and subsequent apoptosis in normal and malignant T-lymphocytes. Photochem Photobiol 1996: 63: 566-571.
10. Jeffes EW 3rd, McCullough JL, Pittelkow MR, et al. Methotrexate therapy of psoriasis: differential sensitivity of proliferating lymphoid and epithelial cells to the cytotoxic and growth-inhibitory effects of methotrexate. J Invest Dermatol 1995: 104: 183-188.
11. Hodak E, Gottlieb AB, Segal T, et al. Climatotherapy at the Dead Sea is a remittive therapy for psoriasis: combined effect on epidermal and immunologic activation. J Am Acad Dermatol 2003: 49: 451-457.
12. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995: 1: 442-447.
13. Chisholm PL, Williams CA, Jones WE, et al. The effects of an immunomodulatory LEAS-IgG1 fusion protein on non-human primates. Ther Immunol 1994: 1: 205-216.
14. Meier W, Gill A, Rogge M, et al. Immunomodulation by LFA3TIP an LEA-3/IgG1 fusion protein: cell line dependent glycosylation effects on pharmacokinetics and pharmacodynamic markers. Ther Immunol 1995: 2: 159-171.
15. Majeau GR, Meier W, Jimmo B, Kioussis D, Hochman PS. Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses: structure/function analysis in vitro and in human CD2 transgenic mice. J Immunol 1994: 152: 2753-2767.
16. Klaplon RJ, Hochman PS, Michler RE, et al. Short course single agent therapy with an LFA-3-IgG1 fusion protein prolongs primate cardiac allograft survival. Transplantation 1996: 61: 356-363.
17. Miller GT, Hochman PS, Meier W, et al. Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses. J Exp Med 1993: 178: 211-222.
18. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Eng J Med 2001: 345: 248-255.
19. Ortonne J-P, Lebwohl M, Griffith CEM. Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. Eur J Dermatol 2003: 13: 117-123.
20. Gordon KB, Vaishnaw AK, O'Gordon J, Haney J, Menter A. Treatment of psoriasis with alefacept. Correlation of clinical improvement with reductions of memory T cell counts. Arch Dermatol 2003: 139: 1563-1570.
21. Kobayashi S, Sugiyama H, Gyulai R, et al. Alefacept treatment for psoriasis reduces the number of infiltrating IFNγ + producing T cells in lesional skin (Abstract). J Invest Dermatol 2001: 117: 546.
22. + T cells (Abstract). J Invest Dermatol 2002: 119: 759.
23. Godekoop AY, De Rie MA., Ricavet DI, et al. Alefacept therapy reduces the effector T cell population in lesional psoriatic epidermis. Arch Dermatol Res 2004; on line February 14 (Epub ahead of print).
24. Krueger GG, Ellis CN. Alefacept therapy produces remission for patients with chronic plaque psoriasis. Br J Dermatol 2003: 148: 784-788.
25. Krueger GG, Gallis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003: 49 (S): 87-97.
26. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of two courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002: 47: 821-833.
27. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003: 139: 719-727.
28. TenHoor C, Vaishnaw A. Tolerability, biologic activity, and pharmacokinetics of alefacept administered as an intravenous infusion, intramuscular injection and intravenous bolus injection (Abstract). J Eur Acad Dermatol Veneral 2001: 15 (Suppl. 2): 24-56.
29. Ortonne J-P. Clinical response to alefacept: results of a phase three study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. J Europ Acad Dermatol Venerolog 2003: 17 (Suppl. 2): 12-16.
30. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in Psoriasis. J Drugs Dermatol 2003: 2 (6): 624-628.
31. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. J Am Acad Dermatol 1999: 41: 51-59.
32. Lowe NJ, Gonzalez J, Bagel J, Caro I, Ellis CN, Menter A. Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy. Int J Dermatol 2003: 42: 224-230.
33. Menter A, Cathor JC. Long-term use of alefacept: safety and off-treatment responses in patients who have received multiple courses of therapy. Poster session, 62nd Annual Meeting of the American Academy of Dermatology, February 11, 2004, Washington, DC.
34. Ormerod AD. Alefacept. Curr Opin Invest Drugs 2003: 4: 608-613.
35. Margolis D, Bilker W, Herrnessy S, Vittorio C, Sanntana Storm BL. The risk of malignancy associated with psoriasis. Arch Dermatol 2001: 137: 778-783.
36. Marcil I, Stern RS. Squamous cell cancers of the skin in patients given PUVA and cyclosporine: nested cohort crossover study. Lancet 2001: 358 (9287): 1042-1045.
37. + T cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. J Am Acad Dermatol 2003: 49: 816-825.
38. Gribetz CH, Blum R, Brady C, Cohen S, Lebwohl M. Safety and efficacy of an extended 16-week course of alefacept in the treatment of chronic plaque psoriasis: an interim analysis. Poster presentation, 62nd Annual Meeting of the American Academy of Dermatology, Washington DC, February, 2004.
39. Langley R, Baker D, Roberts J. The safety of alefacept using a reduced schedule for monitoring T cells. Poster presentation, 62nd Annual Meeting of the American Academy of Dermatology, Washington DC, February, 2004.
40. Koo J. Combination therapy with alefacept plus broad-band ultraviolet B light for treatment of psoriasis. Presented at International Psoriasis Symposium, New York, June, 2003.
41. Ortonne J-P, Khemis A. Combination therapy with alefacept plus narrowband ultraviolet B light for the treatment of psoriasis. Presented at International Psoriasis Symposium, New York, June, 2003.
42. Gottlieb AB. Alefacept in combination with tapering doses of cyclosporine in patients with psoriasis. Poster presentation, 62nd Annual Meeting of the American Academy of Dermatology, Washington DC, February, 2004.
43. Menter A, Abramovitz W, Cather JC. Alefacept in combination with tapering doses of methotrexate in patients with psoriasis. Poster presentation, 62nd Annual Meeting of the American Academy of Dermatology, Washington DC, February, 2004.